{
    "ticker": "LIXT",
    "name": "Lixte Biotechnology Holdings, Inc.",
    "description": "Lixte Biotechnology Holdings, Inc. is a clinical-stage biotechnology company focused on discovering and developing novel cancer therapies. Founded in 2008 and headquartered in East Setauket, New York, Lixte is dedicated to addressing significant unmet needs in cancer treatment through its innovative drug development platform. The company\u2019s lead product candidate, LB-100, is a novel therapeutic agent that targets cancer metabolism and has shown promising results in preclinical studies and early-stage clinical trials. Lixte is also exploring other compounds that may have potential in treating various types of cancer, including those that are resistant to current therapies. The company aims to develop its products through rigorous scientific research and collaboration with clinical partners. By leveraging its proprietary technology and understanding of cancer biology, Lixte strives to bring forward new treatment options that can improve patient outcomes and enhance the quality of life for cancer patients. As cancer remains one of the leading causes of mortality globally, Lixte's commitment to developing innovative therapies is critical in the fight against this disease.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "East Setauket, New York, USA",
    "founded": "2008",
    "website": "https://www.lixte.com",
    "ceo": "John S. Kovach, M.D.",
    "social_media": {
        "twitter": "https://twitter.com/LixteBio",
        "linkedin": "https://www.linkedin.com/company/lixte-biotechnology-holdings-inc"
    },
    "investor_relations": "https://www.lixte.com/investor-relations",
    "key_executives": [
        {
            "name": "John S. Kovach, M.D.",
            "position": "CEO"
        },
        {
            "name": "Gail S. K. L. B. K. M. A. L. C. M. D.",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Cancer Therapies",
            "products": [
                "LB-100"
            ]
        }
    ],
    "seo": {
        "meta_title": "Lixte Biotechnology Holdings, Inc. | Innovative Cancer Therapies",
        "meta_description": "Learn about Lixte Biotechnology Holdings, Inc., a clinical-stage biotech company developing novel therapies for cancer treatment. Explore their innovative approaches and lead product candidate LB-100.",
        "keywords": [
            "Lixte Biotechnology",
            "Cancer Therapy",
            "LB-100",
            "Biotechnology",
            "Pharmaceuticals"
        ]
    },
    "faq": [
        {
            "question": "What does Lixte Biotechnology focus on?",
            "answer": "Lixte Biotechnology focuses on discovering and developing novel cancer therapies."
        },
        {
            "question": "What is Lixte's lead product candidate?",
            "answer": "Lixte's lead product candidate is LB-100, a novel therapeutic agent targeting cancer metabolism."
        },
        {
            "question": "Where is Lixte headquartered?",
            "answer": "Lixte is headquartered in East Setauket, New York, USA."
        },
        {
            "question": "When was Lixte founded?",
            "answer": "Lixte was founded in 2008."
        }
    ],
    "competitors": [
        "CLLS",
        "CRMD",
        "SRNE",
        "XLRN"
    ],
    "related_stocks": [
        "AMGN",
        "ABBV",
        "MRK",
        "BMY"
    ]
}